Neuronal calcium sensor-1 enhancement of InsP3 receptor activity is inhibited by therapeutic levels of lithium by Schlecker, Christina et al.
Research article
1668	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 116	 	 	 Number 6	 	 	 June 2006
Neuronal calcium sensor-1 enhancement  
of InsP3 receptor activity is inhibited  
by therapeutic levels of lithium
Christina Schlecker,1,2,3 Wolfgang Boehmerle,1,4 Andreas Jeromin,5 Brenda DeGray,1  
Anurag Varshney,1 Yogendra Sharma,6 Klara Szigeti-Buck,7 and Barbara E. Ehrlich1,3
1Department of Pharmacology, Yale University, New Haven, Connecticut, USA. 2Department of Neuroscience, University of Magdeburg, Magdeburg, Germany. 
3Neurosciences Institute of the Marine Biological Laboratory, Woods Hole, Massachusetts, USA. 4Institute for Neurophysiology,  
Charité Universitätsmedizin Berlin, Berlin, Germany. 5Center for Learning and Memory, University of Texas at Austin, Austin, Texas, USA.  
6Center for Cellular and Molecular Biology, Hyderabad, India. 7Obstetrics and Gynecology, Yale University, New Haven, Connecticut, USA.
Regulation	and	dysregulation	of	intracellular	calcium	(Ca2+)	signaling	via	the	inositol	1,4,5-trisphosphate	
receptor	(InsP3R)	has	been	linked	to	many	cellular	processes	and	pathological	conditions.	In	the	present	
study,	addition	of	neuronal	calcium	sensor-1	(NCS-1),	a	high-affinity,	low-capacity,	calcium-binding	protein,	
to	purified	InsP3R	type	1	(InsP3R1)	increased	the	channel	activity	in	both	a	calcium-dependent	and	-indepen-
dent	manner.	In	intact	cells,	enhanced	expression	of	NCS-1	resulted	in	increased	intracellular	calcium	release	
upon	stimulation	of	the	phosphoinositide	signaling	pathway.	To	determine	whether	InsP3R1/NCS-1	inter-
action	could	be	functionally	relevant	in	bipolar	disorders,	conditions	in	which	NCS-1	is	highly	expressed,	
we	tested	the	effect	of	lithium,	a	salt	widely	used	for	treatment	of	bipolar	disorders.	Lithium	inhibited	the	
enhancing	effect	of	NCS-1	on	InsP3R1	function,	suggesting	that	InsP3R1/NCS-1	interaction	is	an	essential	
component	of	the	pathomechanism	of	bipolar	disorder.
Introduction
Calcium is a ubiquitous intracellular signaling molecule that is 
required for initiating and regulating a wide range of neuronal func-
tions, including neurotransmitter release, synaptic plasticity, neurite 
outgrowth, and neurodegeneration (1, 2). Considering the impor-
tance of calcium signals for cellular functions, it is not surprising that 
the inositol 1,4,5-trisphosphate receptor (InsP3R) is also involved in 
pathological conditions that are related to disturbance in calcium 
homeostasis. Loss of InsP3R type 1 (InsP3R1) in mice is associated with 
ataxia and seizures (3), and loss of InsP3R3 is found in humans with 
bile duct obstruction (4). In several neurodegenerative diseases, such 
as Alzheimer disease and Huntington disease, and in brain ischemia, 
InsP3R1 appears to be selectively downregulated (5–7). Understand-
ing the basis for the dysregulation of InsP3R activity will be crucial for 
understanding the pathomechanism of these diseases.
A variety of signaling molecules have been shown to associate with 
InsP3R and modulate its activity (8, 9); the most studied of these 
regulators is calcium, which influences channel activity both as an 
activator and an inhibitor, both directly and indirectly. A number 
of potential cofactors necessary for calcium-dependent modulation 
have been identified (8, 10, 11). Recently, neuronal calcium sensor-1 
(NCS-1) has been shown to regulate intracellular calcium signaling 
(8, 12, 13). This protein contains EF hand motifs for rapid binding 
of calcium that results in major conformational changes in NCS-1 
(14). Mutations in NCS-1 have been linked to pathological condi-
tions, including human X-linked mental retardation (15). In chronic 
bowel disease, the expression level of NCS-1 in the enteric nervous 
system is drastically decreased (16), causing diminution in neu-
rotransmitter secretion. In contrast, NCS-1 expression is increased 
in the prefrontal cortex of schizophrenic and bipolar patients (17). 
Unfortunately, little is known about the underlying pathomecha-
nism of these human diseases although misregulation of calcium 
homeostasis has been proposed to play a role (18, 19).
To determine whether NCS-1 and InsP3R1 functionally inter-
act with each other and whether this interaction could be altered 
under neuropathological conditions, we examined the effect of 
NCS-1 on the single-channel properties of InsP3R and on agonist-
dependent intracellular release in cells. Since NCS-1 is upregulated 
in bipolar disorders and one of the first successful medications 
for this condition was lithium, which is still widely used, we test-
ed the effect of lithium on the functional interactions between 
NCS-1 and InsP3R1. Lithium has already been shown to interact 
with the phosphoinositol signaling pathway (20) by inhibiting 
phosphoinositol lipid turnover. The effects of lithium on NCS-1/
InsP3R1 interactions would complement the lipid effects and add 
a new pathway to be explored for therapeutic potential.
We found that addition of NCS-1 enhances the activity of the 
InsP3R1, when monitored as the activity of single channels and 
as calcium transients in intact cells. This modulation is InsP3- 
and calcium-dependent such that InsP3-activated responses will 
be larger and more rapid due to NCS-1–enhanced activation of 
the InsP3R1. We also found that lithium attenuates the NCS-1/
InsP3R1 association. This observation indicates that the signaling 
complex comprised of NCS-1 and the InsP3R may be involved in 
the pathomechanism of bipolar disorders.
Results
Brain slices of adult rats were immunostained to show the colo-
calization of NCS-1 and InsP3R1 in vivo. In the cerebellum, NCS-1 
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was visible throughout the cell except the nucleus in Purkinje 
cells and stellate cells (Figure 1). InsP3R1 was also found through-
out the cell but with stronger staining in the cell body. Both pro-
teins were detected in neurons of the hippocampus and deep 
layers of the prefrontal cortex (data not shown). Neurons in the 
upper layers of the cortex showed marked InsP3R1 staining but 
no or little NCS-1 staining. These observations agree with previ-
ous reports about the cell type–specific expression of NCS-1 (21, 
22). To show that there is a physical interaction between NCS-1 
and InsP3R1, both NCS-1 and InsP3R1 were immunoprecipitated 
from cerebellar lysate. Both proteins were present in mouse cer-
ebellar lysate (Figure 2). When calcium was present in the buffer, 
both proteins were present in the immunoprecipitate when using 
either anti–NCS-1 or anti-InsP3R1 (Figure 2). When calcium lev-
els were low due to the addition of calcium buffers, only the pro-
tein directly associated with the immunoprecipitating antibody 
was present (Figure 2). An additional band at 25 kDa was present 
in all antibody-treated lanes, including the control lane, which is 
neither NCS-1 nor InsP3R. These results show that the interac-
tion between NCS-1 and InsP3R1 can be identified in native tis-
sue and is calcium dependent.
To determine whether the interaction between NCS-1 and 
InsP3R1 has a functional component, we added purified NCS-1 
to InsP3R1 after it had been incorporated into planar lipid bilay-
ers and monitored InsP3-gated channel activity. Measurements 
were obtained using 300 nM free calcium, 0.5 mM ATP, and 2 μM 
InsP3 on the cytoplasmic side of InsP3R1. In the absence of NCS-1, 
the amplitude of the single-channel currents was 2 pA (Figure 3A), 
the open probability (Po) was 4.0% ± 0.6% (n = 3; Figure 3, A and C), 
and the mean open time was 2.5 ms ± 0.3 ms (n = 3; Figure 3, 
A and B). Addition of NCS-1 (2 μg/ml) to the cytoplasmic side of 
the channel increased InsP3R1 channel activity: the Po was dra-
matically increased by a factor of 5 (21.0% ± 1.7%; n = 4; Figure 3, 
A and C), and the mean open time increased to 6.0 ms ± 0.6 ms 
(n = 4; Figure 3B). The amplitude of the single-channel currents 
remained unaltered (Figure 3A). The ability of NCS-1 to activate 
the channel was unchanged even when the NCS-1 concentration 
was varied from 0.45 μg/ml to 2.56 μg/ml. The enhancing role of 
NCS-1 on InsP3R1 channel activity could, in principle, be attrib-
uted to the ability of NCS-1 to activate the channel in the absence 
of InsP3. When NCS-1 was added to InsP3R1 in the absence of 
InsP3 over a range of calcium concentrations, no channel open-
ings were observed (Figures 3A and 4C), showing that NCS-1 
alone was unable to activate InsP3R1.
When NCS-1 was tested on the 
activity of the ryanodine recep-
tor type 2 (RyR2), there was no 
change in RyR2 channel activ-
ity at any calcium concentration 
tested (Figure 3D); the bell-shaped 
calcium-dependence curve of the 
RyR2 remained unaltered (data not 
shown). These results indicate that 
the NCS-1/InsP3R1 interaction is 
functionally specific.
To test the requirement for cal-
cium binding to NCS-1, we moni-
tored channel activity over a range 
of calcium concentrations, and 
we used a mutated form of NCS-1 
with a point mutation in EF hand 3 (E120Q). This mutation 
results in a protein with reduced calcium-binding ability but an 
unaltered calcium-dependent conformational change and unal-
tered ability to bind to protein partners (23). After addition of 
the E120Q mutant to InsP3-activated channel at 300 nM free 
calcium, the Po increased to 8.0 % ± 1.7% (n = 3; Figures 3A and 4, 
A and C), but the mean open time was unchanged (2.2 ms ± 0.3 ms; 
n = 3; Figure 3B). When the free calcium concentration was raised 
serially from 0.01 μM to 1000 μM in the presence of 2 μg NCS-1, 
there was an increase in Po (up to 41% ± 0.05% at 1000 μM 
calcium; n = 4) and mean open time (Figure 4, A–C). When the 
channel properties are plotted as a function of the free calcium 
concentration, 2 plateaus appear at pCa 6.5 and 4 (where pCa is 
the negative log of the free calcium concentration) that are com-
parable to the calcium-binding sites of the purified NCS-1 (24). 
In contrast, when E120Q was used, the Po and mean open time 
remained constant as the calcium concentration was increased 
(Figure 4, A–C). Thus, NCS-1 acts on InsP3R1 in both a calcium-
independent and a calcium-dependent manner.
To determine whether the interaction between NCS-1 and 
InsP3R1 was functional in vivo, we monitored agonist-induced 
calcium release in nerve growth factor–differentiated (NGF-dif-
ferentiated) PC12 cells. Both proteins were detected in these cells 
(Figure 5A). PC12 cells that stably overexpressed NCS-1 were 
Figure 1
Immunolocalization of NCS-1 and InsP3R1 in neurons in vivo. Slices from cerebellum of adult rat brain 
were immunostained for NCS-1 (far left) and InsP3R (second from left). Both proteins were found 
throughout the cerebellum with an overlapping distribution (second from right) but were concentrated in 
Purkinje cells (see detail of single cell in far right panel).
Figure 2
Coimmunoprecipitation of NCS-1 and InsP3R1 in rat cerebellum. Lanes 
show mouse cerebellar lysate (lane 1); beads treated with cerebellar lysate 
but without antibody (lane 2); immunoprecipitate (IP) with anti–NCS-1 
with calcium buffered (lane 3); immunoprecipitate with anti–NCS-1 with 
50 μM free calcium present (lane 4); immunoprecipitate with anti-InsP3R 
with calcium buffered (lane 5); and immunoprecipitate with anti-InsP3R 
with 50 μM free calcium present (lane 6). Top and bottom panels show 
immunoblots for InsP3R1 and NCS-1, respectively.
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stimulated with 50 μM ATP for 1 minute, and the changes in 
cytosolic calcium levels were monitored using Fluo-4, a calcium-
sensitive fluorescence dye. PC12 cells stably expressing the empty 
vector were used as controls. Cells containing NCS-1 showed a 
larger response to ATP stimulation than control cells (Figure 5B: 
all values presented as maximum ratio of fluorescence intensity 
over baseline [F/F0], 1.5 ± 0.06 for control cells, n = 37; 3.8 ± 0.5 for 
NCS-1 cells, n = 22). Removal of ATP from the chamber reduced 
the fluorescence to baseline levels. These results show that the 
functional effects of NCS-1 on InsP3R1 observed using purified 
proteins are maintained in intact cells.
NCS-1 may play a role in the pathophysiology of several neu-
ropsychiatric disorders (17). Because lithium has been used for 
the treatment of bipolar disorders for more than 50 years, we 
tested its effects on the ability of NCS-1 to enhance the activity of 
InsP3R1. InsP3R1 channel activity increased at least 2-fold after 
addition of NCS-1 (Figure 3A). Addition of lithium offset the 
enhancing effects of NCS-1 on InsP3R1 channel activity to near 
baseline levels (5% ± 2.1%, n = 3; Figure 6B). This inhibitory effect 
of lithium on the NCS-1 action was strongly dependent on the 
lithium concentration, with an IC50 of 350 μM (Figure 6C). In 
the absence of NCS-1, addition of lithium had no effect on InsP3-
gated channel activity (Figure 6C). Similarly, lithium significant-
ly decreased the amplitude of the calcium-induced fluorescence 
change in cells overexpressing NCS-1 (3.8 ± 0.56 before lithium 
incubation, 1.9 ± 0.1 after cells were incubated in 10 mM lithium 
for 30 minutes before stimulation; 
Figure 5, C and D; n = 18). Lithium 
had no effect on the intracellular 
calcium transients in control cells 
(1.5 ± 0.06 before lithium incu-
bation, 1.4 ± 0.06 after lithium 
incubation; n = 22). To test the 
possibility that pretreatment with 
lithium would alter the calcium 
concentration in the intracellular 
stores, the stores were depleted of 
intracellular calcium by treatment 
with 1 μM thapsigargin for 2 min-
utes. The maximum amplitude of 
measured fluorescence change was 
1.4 ± 0.03 (n = 31) in control cells 
and 1.7 ± 0.06 (n = 59) in cells pre-
treated with 10 mM lithium for 30 
minutes. With the slight elevation 
of calcium in the stores after lith-
ium treatment, the calcium signal 
after ATP stimulation should have 
increased rather than decrease as 
observed (Figure 5).
Lithium did not alter the abil-
ity of NCS-1 to immunoprecipitate 
InsP3R1 (Figure 6A). To determine 
whether lithium binds to NCS-1, 
we monitored the change in Trp 
fluorescence of NCS-1. Lithium 
decreased the fluorescence emis-
sion of NCS-1 to the same degree 
as calcium (25, 26) irrespective of 
the presence or absence of physi-
ological levels of calcium (350 nM; data not shown). Addition of 
calcium in the presence of therapeutic levels of lithium (1 mM) 
produced no further decrease in fluorescence emission. These data 
are consistent with a model where lithium has fixed the NCS-1 
in a calcium-independent state that then attenuates activity- and 
NCS-1–dependent changes in InsP3R1. Further experiments are 
required to identify the binding sites and the affinity of NCS-1 for 
lithium in the presence and absence of calcium.
Discussion
Our experiments show that NCS-1 modulates calcium signaling by 
enhancing InsP3-mediated activity of InsP3R1 and thereby ampli-
fying the calcium signal. This modulation is calcium dependent 
such that elevated cytosolic calcium concentrations will increase 
even more rapidly due to enhanced NCS-1 activation of InsP3R1. 
Furthermore, we found that lithium attenuates the NCS-1/InsP3R 
association, suggesting that the interaction is associated with the 
pathomechanism of bipolar disorders.
Calcium is a major intracellular messenger that is involved in 
the regulation of many cellular functions, some of which appear 
to be opposing functions, such as apoptosis and cell prolifera-
tion (2). One way that a single molecule such as calcium could 
be used to orchestrate such diverse signals and regulate so com-
pletely dissimilar cellular processes is by modulating the spatial 
and temporal pattern of the calcium signals. For that purpose, 
the existence of a large “calcium-signaling toolkit” (9) has been 
Figure 3
Effect of NCS-1 and the E120Q mutant of NCS-1 on the activity of InsP3R1. (A) Single-channel record-
ings of InsP3R1 where downward deflections are channel openings. The top pair of traces on the 
left were recorded after addition of 300 nM free calcium and 2 μM InsP3, and the bottom left pair of 
traces show activity after addition of 2 μg/ml NCS-1 in the presence of 2 μM InsP3. In each case, the 
uppermost trace represents 10 seconds of continuous recording, and the bottom trace shows a 10-fold 
expansion of the time scale. On the right, the top pair of traces were recorded in the presence of 2 μg/ml 
NCS-1 in the absence of InsP3, and the bottom pair of traces were recorded after addition of 2 μg/ml 
E120Q, a mutant of NCS-1, in the presence of 2 μM InsP3. Averaged values from at least 3 experiments 
for mean open time (B) and for Po (C) of InsP3R1 corresponding to the traces shown in A. Note that 
NCS-1 alone did not activate InsP3R1. (D) Addition of NCS-1 (2 μg/ml) had no effect on the activity of 
the RyR2 activated by 300 μM calcium.
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suggested, where the selected tools would be unique for a given 
cell type. We suggest that NCS-1 is one of the proteins that mod-
ulate calcium signaling.
NCS-1, a member of the family of calcium-binding proteins, is 
predominantly expressed in neurons and neuroendocrine cells (27, 
28). It is involved in many diverse neuronal signaling pathways 
from modulation of neurotransmitter release (29) to attenuation of 
dopamine receptor desensitization (30). In cultured hippocampal 
neurons, synapses with elevated levels of NCS-1 show paired-pulse 
facilitation whereas synapses with little NCS-1 respond to repetitive 
stimulation with depression. This phenomenon can be explained 
by elevated calcium levels at synapses overexpressing NCS-1. 
Based upon the results presented here, the molecular basis for the 
observed switch is likely to be the NCS-1–induced enhancement of 
InsP3R1 activity. Other phenomena may also be regulated by NCS-1 
levels. For example, Caenorhabditis elegans	overexpressing NCS-1 
shows improved memory whereas NCS-1 knockout animals display 
impaired memory function. In humans, the highest levels of NCS-1 
are found in brain regions such as the hippocampus and areas that 
are associated with memory and sensory processing (31).
Other members of the calcium-binding protein family have func-
tional effects on InsP3R (8, 13, 25, 32). An initial report suggested 
that calcium-binding protein 1 (CaBP1) could activate InsP3R, even 
in the absence of InsP3 (32), but subsequent reports have shown that 
CaBP1 is an effective inhibitor of calcium release through InsP3R 
and that InsP3 is required for this effect (8, 25). Comparisons of the 
properties of CaBP1 and NCS-1 showed that the calcium-binding 
affinity was similar, but when cells were maximally stimulated to 
release intracellular calcium (25), expression of CaBP1 inhibited 
the response whereas expression of NSC-1 enhanced the respon-
Figure 4
Calcium dependence of the effect of NCS-1 and its 
E120Q mutant on InsP3R1. Single-channel recordings of 
InsP3R1 at the calcium concentrations indicated in the fig-
ure in the presence of E120Q and InsP3 (A, left traces) or 
NCS-1 and 2 μM InsP3 (A, right traces). Averaged values 
from at least 3 experiments for the mean open time (B) 
and the Po (C) are shown for the effect of the addition of 
either NCS-1 (open circles) or the mutant form E120Q 
(filled circles). There is a calcium-independent activation 
as shown at low calcium concentrations after addition of 
E120Q and a calcium-dependent activation shown after 
addition of NCS-1. The purified InsP3R1 used in this study 
displays no inhibition at calcium levels over the negative 
log of the free calcium concentration (pCa) 6.5 (black line; 
data taken from ref. 40).
Figure 5
PC12 cells overexpressing NCS-1 show increased intracellular calcium 
release after stimulation by extracellular ATP. (A) Wild-type PC12 cells 
contain both NCS-1 (green) and InsP3R1 (red). Scale bar: 50 μm. (B) 
Representative traces showing calcium release evoked by the addition 
of 50 μM ATP for 1 minute followed by a washout (dark trace: PC12 
cells overexpressing NCS-1; light trace: PC12 cells transfected with 
empty vector). (C) Representative traces comparing the intracellular 
calcium release after preincubation with lithium (30 minutes, 10 mM 
lithium; light trace) with NCS-1 cells that were not treated with lithium 
(dark trace). Note that lithium did not alter the fluorescence signal but 
did decrease the NCS-1–dependent increase in calcium release to 
control levels. (D) Averaged values from at least 3 experiments.
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siveness of the cells (8, 25). This diversity of effect allows the numer-
ous members of the calcium-binding protein family to be specific 
yet potent regulators of InsP3R function.
The interactions between NCS-1 and InsP3R are not only of 
importance for physiological functions in neurons, but accumu-
lating evidence suggests an association with pathological condi-
tions. Recently, NCS-1 levels have been shown to be increased 
in the prefrontal cortex of schizophrenic and bipolar patients 
(17). Both conditions are also associated with disturbances in 
calcium homeostasis and alterations in the phosphoinositide 
signaling pathway (19, 33). Platelets of affected people are often 
used as models for neurons because they have similar signaling 
features and it is possible to obtain samples from affected indi-
viduals. In platelets from unmedicated patients, the increase in 
intracellular calcium after thrombin stimulation is significantly 
higher than that measured in healthy controls (33). Our obser-
vations can explain these phenomena with the enhancing effect 
of NCS-1 on InsP3R1 activity, which affects intracellular calcium 
release but not resting calcium levels.
It now appears that NCS-1 plays a multifaceted role in the 
pathophysiology of neuropsychiatric disorders. Our results show 
that lithium, a commonly used therapeutic reagent for bipolar dis-
ease, antagonizes NCS-1–mediated InsP3R1 enhancement by alter-
ing the calcium-dependent properties of NCS-1. That therapeutic 
levels of lithium could inhibit this property of NCS-1 even in the 
presence of physiological levels of calcium shows the importance 
of the activity of this family of proteins and their interactions with 
target proteins. Our experiments using the calcium-binding defi-
cient NCS-1 (E120Q mutant) lend further support for the impor-
tance of the regulation of the calcium-binding proteins on the 
activity of InsP3R1. We conclude that the positive enhancement of 
InsP3R1 action by NCS-1 is a widely used mechanism to increase 
calcium signals and is important in many physiological processes. 
The role of NCS-1 in pathological conditions suggests that it is a 
promising target for treatment of neuropsychiatric disorders.
Methods
Immunoprecipitation and immunocytochemistry. Microsomes were made from 
mouse cerebella as previously described (34). Cerebellar lysates were made 
by homogenization of mouse cerebella in RIPA buffer (Santa Cruz Bio-
technology Inc.), followed by 2 spins at 16,000 g for 5 minutes at 4°C. For 
immunoprecipitation, either the cerebellar microsomes or lysates were incu-
bated with antibody; the 2 antibodies used were anti–NCS-1 (Santa Cruz 
Biotechnology Inc.) and anti-InsP3R type I (35). The immunoprecipitates 
were resolved by SDS-PAGE and transferred to a PVDF membrane, and 
immunoreactive bands were visualized using standard methods. Frozen 
mouse cerebella were purchased from Pel-Freeze Biologicals.
Anti–NCS-1 or anti-InsP3R type I antibodies (from the same sources as 
above) were used to probe fixed rat brain slices or PC12 cells. PC12	cells were 
differentiated with 100 ng/ml NGF (New England Biolabs Inc.) for 5 days 
prior to fixation. Tissue samples were prepared as previously described (36).
Purification of the proteins and measurement of NCS-1 properties. InsP3R were 
purified and reconstituted as described previously (37). Similarly, NCS-1 
was produced and purified as described previously (38). Lithium binding 
Figure 6
Lithium reduces the NCS-1–mediated increase in InsP3R1 activity. (A) Addition of lithium (concentrations as indicated) did not alter the ability of 
NCS-1 to immunoprecipitate InsP3R1. (B) Single-channel recordings of InsP3R1. Traces show the activity in the presence of 300 nM free calcium, 
2 μM InsP3, and 2 μg/ml NCS-1 and were recorded after addition of 1 μM, 200 μM, and 1 mM lithium (in the top, middle, and bottom panels, respec-
tively). (C) Averaged values from at least 3 experiments for Po. The concentration dependence for lithium on the NCS-1–mediated enhancement 
of InsP3R activity in the presence (open circles) and absence (filled circles) of NCS-1. The IC50 for lithium was approximately 350 μM.
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to NCS-1 was monitored by fluorescence spectroscopy. NCS-1 protein was 
suspended in 50 mM Tris and 100 mM KCl, pH 7.2, and was titrated with 
the desired concentrations of lithium and incubated for 5 minutes; emis-
sion spectra were recorded at the excitation of 280 and 295 nm.
Single-channel measurements. Planar lipid bilayers were formed by painting a 
solution of phosphatidylethanolamine/phosphatidylserine (3:1; 30 mg/ml 
in decane) across a 200-μm hole in the side of a polystyrene cup (Warner 
Instruments) separating 2 chambers with a volume of 1 ml each. Then the 
purified InsP3R1 were incorporated into the bilayer (37). After addition of 
InsP3, InsP3R1 was activated, and single-channel activity was recorded. NCS-1 
was then added to the cytoplasmic side of the channel. For the NCS-1 
concentration-response curve, channel activity was recorded after adding NCS-1 
to a final concentration of 0.45 μg/ml, 0.9 μg/ml, 1.34 μg/ml, 1.92 μg/ml, 
and 2.56 μg/ml. The free calcium concentration was kept constant at 300 nM, 
and InsP3 concentration was 2 μM. For the calcium concentration-response 
curve, channel activity was recorded after the free calcium concentration 
was incrementally increased (10 nM, 30 nM, 100 nM, 300 nM, 1 μM, 
3 μM, 10 μM, 30 μM, 100 μM, 300 μM, and 1000 μM) at a fixed NCS-1 
concentration of 2 μg and a constant InsP3 concentration of 2 μM. These 
experiments were repeated using the E120Q mutant of NCS-1 to determine 
the effect of calcium on NCS-1. To examine the ability of NCS-1 to activate 
InsP3R1 in the absence of InsP3, channel activity was first observed in the 
presence of InsP3. Then, after InsP3 was removed, NCS-1 alone was added, 
and the level of channel activity was recorded.
To examine the effect of lithium on the ability of NCS-1 to alter channel 
activity, lithium was added to the cytoplasmic side incrementally (0.5 mM, 
1 mM, 1.5 mM, 2.5 mM, 4 mM, and 5 mM) in the presence of fixed concen-
trations of InsP3 (2 μM), calcium (300 nM), and	NCS-1 (1.92 μg/ml). The 
effect of lithium was also tested in the absence of NCS-1.
Cell culture and generation of NCS-1 and E120Q overexpressing PC12 cells. 
PC12 cells were grown as described previously (39), and stable transfect-
ed PC12 cells were obtained as reported (13). Cells were detached using 
0.25% trypsin/1 mM EGTA (Invitrogen Corp.) and plated on glass cover 
slips (Fisher Scientific International) in a dilution of 30,000 cells/ml. 
The plated cells were differentiated with 100 ng/ml NGF (New England 
Biolabs Inc.) for 5 days.
Calcium imaging. Confocal microscopy was used to measure intracellular 
calcium in PC12 cells (35). Differentiated PC12 cells were loaded with 
Fluo-4 AM (Invitrogen Corp.)	and then mounted onto the stage of a Zeiss 
Axiovert 135 inverted microscope. The cells were perfused continuously 
with artificial cerebrospinal fluid (124 mM NaCl, 10 mM glucose, 25 mM 
NaHCO3, 1.25 mM NaH2PO4, 2.5 mM KCl, 2 mM CaCl2, and 2 mM MgCl2; 
pH 7.35) using a 4-chambered superfusion reservoir that allowed rapid 
changes of perfusion solutions. Cells were stimulated with 50 μM ATP for 
1 minute. Increases in calcium were expressed as the ratio of fluorescence 
intensity to baseline (F/F0). Background fluorescence was automatically 
subtracted from all measurements. There was no change in size, shape, or 
location of cells during the experiments.
To determine the effect of lithium on ATP-evoked calcium release, cells 
were preincubated in growth medium containing 10 mM lithium for 15 
minutes. The cells were then loaded with Fluo-4 and monitored as described 
above, except that the dye solution was supplemented with 10 mM lithium.
Statistics. All averaged values shown are mean ± SEM. Each value for bilay-
er experiments represents an average of at least 3 experiments; for calcium 
imaging, at least 10 experiments were averaged.
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